Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
US Stock Insider Trading | Novavax Pharmaceuticals disclosed five insider transactions on March 5
On March 5, 2026, Novavax, Inc. (NVAX) disclosed five corporate insider transactions. On March 3, 2026, director Jacobs John C sold 69.3k shares.
【Recent Insider Transactions】
【Company Profile】
Novavax, Inc. was incorporated in 1987 under the laws of the State of Delaware in the United States. It is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company’s vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology, including virus-like particles (VLP) and protein nanoparticle candidate vaccines. The company’s candidate vaccines are genetically engineered three-dimensional nanostructures that include immunologically important proteins. The company’s vaccine product pipeline targets multiple infectious diseases, and its candidate drugs are currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, and pandemic influenza. In addition, the company’s joint venture in India, CPL Biologics Private Limited (CPLB), is actively developing multiple candidate vaccines, which are genetically engineered by Novavax, Inc.